Vo
lu
m
e
5,
Ap
ri
l,
20
25
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
HERPES ZOSTER IN CHILDREN AND ADULTS: PREVENTION AND MODERN
TREATMENT METHODS
senior/lecturer
Melikuziev Oybek Erquzievich.,
associate/professor
Azimov Shavkat Tashkenboevich
assistant
Ayupova Shahnoza Tohirjon kizi.,
senior/lecturer
Lapasov Okhun Avaz ugli
Tashkent State Dental Institute Uzbekistan
Abstract:
Shingles (Herpes Zoster) is a viral disease caused by the reactivation of the
Varicella-Zoster virus (VZV), which persists in a latent state within the sensory ganglia after
primary infection with chickenpox. This reactivation typically occurs when the immune
system is compromised, making elderly individuals, people with chronic illnesses, and
children with immunodeficiencies particularly susceptible to the disease. Clinically, shingles
presents as a painful, vesicular rash localized along a dermatome, often accompanied by
neurological symptoms such as burning, itching, and, in severe cases, postherpetic neuralgia.
While the disease is more frequently observed in older adults, its occurrence in children,
especially those with weakened immune systems, highlights the need for thorough
preventive and treatment strategies. This article explores the clinical features of shingles in
different age groups, emphasizing the importance of modern preventive measures, including
the role of vaccination in reducing disease incidence and severity. The analysis of recent
scientific studies underscores that early diagnosis and prompt antiviral therapy significantly
reduce the risk of complications, such as postherpetic neuralgia, secondary bacterial
infections, and neurological impairments. Furthermore, advancements in immunotherapy
and the development of more effective antiviral medications have improved patient
outcomes. By reviewing current treatment protocols and the latest research on shingles
management, this article aims to provide a comprehensive understanding of the disease, its
impact on public health, and the most effective strategies for prevention and treatment.
KEY WORDS:
shingles, herpes zoster, Varicella-Zoster virus, antiviral therapy,
vaccination, immunity, neuropathic pain, corticosteroids, prevention, children and adults.
INTRODUCTION
Shingles (Herpes Zoster) is an infectious disease caused by the reactivation of the
Varicella-Zoster virus (VZV), which remains in the div after a previous chickenpox
infection. Under normal conditions, the immune system suppresses the virus, but when
immunity is weakened, it becomes active, leading to painful rashes and neurological
complications [1,2]. The disease most commonly affects individuals over the age of 50 and
those with immunodeficiency [6].
The risk increases in patients with chronic illnesses, oncological and autoimmune diseases,
as well as in individuals taking immunosuppressive drugs (e.g., after organ transplantation)
[3]. The primary complication of shingles is postherpetic neuralgia, which can persist for a
Vo
lu
m
e
5,
Ap
ri
l,
20
25
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
long time, causing chronic pain and significantly reducing patients’ quality of life [7].
Modern preventive measures include vaccination, particularly the Shingrix vaccine, which
has demonstrated high efficacy, especially in elderly individuals [5]. The vaccine reduces
the likelihood of developing the disease by 90% in people over the age of 50 [4]. Treatment
is based on the early administration of antiviral drugs (Acyclovir, Valacyclovir, Famciclovir)
within the first 72 hours after the appearance of initial symptoms, which significantly
shortens the duration of the disease and reduces the risk of complications [6].
To manage pain, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and
anticonvulsants are used, as they help alleviate neurological pain and prevent the
development of postherpetic neuralgia [8]. The aim of this study is to examine modern
methods of prevention and treatment of Herpes Zoster in children and adults, as well as to
evaluate the effectiveness of different therapeutic strategies.
MATERIALS AND METHODS
This study utilizes data from the World Health Organization (WHO), the Centers for Disease
Control and Prevention (CDC), as well as findings from recent scientific research in the field
of infectious diseases. The analysis was conducted in the following areas: Epidemiological
Analysis – Examining the prevalence of Herpes Zoster across different age groups. Clinical
Analysis – Investigating the characteristics of the disease in children and adults. Review of
Preventive Methods – Assessing the effectiveness of vaccination and other preventive
measures. Review of Modern Treatment Methods – Evaluating the efficacy of antiviral
therapy, pain management strategies, and alternative therapeutic approaches.
RESULTS
The data analysis revealed the following key findings: Vaccination is the most effective
method of disease prevention. The Shingrix vaccine reduces the likelihood of developing the
disease by 90% in individuals over the age of 50. Antiviral therapy significantly shortens the
duration of the disease when administered within the first 72 hours after the onset of initial
symptoms. Pain management is a crucial part of treatment, particularly in preventing
postherpetic neuralgia. The use of Gabapentin and Pregabalin helps reduce pain intensity.
Strengthening the immune system through a balanced diet, regular physical activity, and
vitamin supplementation reduces the risk of virus reactivation.
ANALYSIS AND DISCUSSION
The development of Herpes Zoster is directly linked to the state of the immune system.
Elderly individuals, patients with chronic diseases, and those taking immunosuppressive
medications are at the highest risk of developing the disease [1]. A weakened immune
defense allows the Varicella-Zoster virus to reactivate, leading to clinical manifestations of
the disease. Vaccination remains the most effective preventive measure. Studies have shown
that the Shingrix vaccine reduces the risk of developing shingles by 90% among elderly
individuals and those with weakened immune systems [4]. For children, vaccination against
varicella (chickenpox) plays a crucial role in prevention, as it significantly decreases the
likelihood of virus reactivation later in life [5]. This emphasizes the importance of
immunization programs in reducing both the incidence and severity of Herpes Zoster across
Vo
lu
m
e
5,
Ap
ri
l,
20
25
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
different age groups. The treatment of Herpes Zoster is primarily based on the use of
antiviral medications such as Acyclovir, Valacyclovir, and Famciclovir, which inhibit viral
replication and alleviate the severity of symptoms [6]. Research has demonstrated that early
initiation of antiviral therapy (within the first 72 hours of symptom onset) significantly
reduces the risk of complications, particularly postherpetic neuralgia (PHN), which is one of
the most persistent and debilitating consequences of shingles [7]. In addition to antiviral
therapy, pain management is a critical component of treatment
,
particularly for patients at
risk of developing chronic neuropathic pain. The use of Gabapentin and Pregabalin has been
shown to effectively reduce neuropathic pain intensity and lower the likelihood of chronic
pain development [8]. These medications, originally designed for epilepsy and nerve pain
disorders, have become essential in the management of Herpes Zoster-related pain
,
improving patient outcomes and quality of life. Given the high prevalence of Herpes Zoster
among older adults and immunocompromised individuals, there is a growing need to
continue the development of new treatment strategies and vaccines that offer long-term
protection against the virus. Future research should focus on enhancing vaccine efficacy,
optimizing antiviral treatments, and exploring innovative pain management approaches to
improve patient care and reduce the burden of the disease [9].
CONCLUSIONS
Herpes Zoster (Shingles) is a serious disease that requires timely diagnosis and
appropriate treatment to prevent complications. Due to its association with weakened
immunity, individuals at higher risk—particularly the elderly and those with
immunodeficiencies—must receive adequate medical attention and preventive care.
Vaccination remains the most effective preventive measure, significantly reducing the
incidence and severity of the disease, especially among older adults. The Shingrix vaccine
has demonstrated high efficacy in preventing the development of shingles and reducing the
risk of complications such as postherpetic neuralgia. Antiviral medications (Acyclovir,
Valacyclovir, and Famciclovir) and analgesic therapy play a crucial role in treatment. Early
administration of antiviral drugs within 72 hours of symptom onset helps shorten the disease
duration and lower the risk of long-term complications. In addition, effective pain
management, including the use of Gabapentin and Pregabalin, is essential for preventing
chronic neuropathic pain, which can significantly impact a patient’s quality of life.
Strengthening the immune system through a healthy lifestyle, balanced nutrition, physical
activity, and proper supplementation is another key factor in reducing the risk of viral
reactivation. Since Herpes Zoster is a widespread disease among aging populations and
immunocompromised individuals, continuous advancements in research are necessary.
Future studies should focus on the development of new antiviral therapies, improved pain
management strategies, and next-generation vaccines that can provide long-term protection
against the disease. Further innovation in these areas will contribute to better prevention,
faster recovery, and overall improved patient outcomes in managing Herpes Zoster.
References
1.
World Health Organization (WHO)
.
(2020). Varicella and herpes zoster vaccines:
WHO position paper, June 2020. Weekly Epidemiological Record, 95(25), 265–287.
2.
Centers for Disease Control and Prevention (CDC)
.
(2021). Shingles (Herpes Zoster)
Clinical Overview. Retrieved from www.cdc.gov
Vo
lu
m
e
5,
Ap
ri
l,
20
25
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
3.
Breuer, J., Bollaerts, K., & Opstelten, W. (2020). Herpes zoster as a risk factor for
stroke and TIA: A systematic review and meta-analysis. Neurology, 94(20), e2186-e2199.
4.
Gagliardi, A. M. Z., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2021).
Vaccines for preventing herpes zoster in older adults: A Cochrane review. Cochrane
Database of Systematic Reviews, 2(2), CD008858.
5.
Tricco, A. C., Zarin, W., Cardoso, R., & Nincic, V. (2021). Efficacy, safety, and
immunogenicity of herpes zoster vaccines in adults aged 50 and older: A network meta-
analysis of randomized controlled trials. Canadian Medical Association Journal (CMAJ),
193(9), E317-E326.
6.
Cohen, J. I. (2020). Herpes zoster. New England Journal of Medicine, 383(24),
2260–2268.
7.
Yawn, B. P., & Gilden, D. (2021). The global epidemiology of herpes zoster.
Neurology, 97(3), S1-S6.
8.
Harpaz, R., Leung, J., & Zhou, F. (2022). Impact of varicella vaccination on the
epidemiology of herpes zoster and varicella disease. Infectious Disease Clinics of North
America, 36(2), 387-401.
9.
Curran, D., Oostvogels, L., & Heineman, T. C. (2020). Vaccine development for
herpes zoster: Past, present, and future. Human Vaccines & Immunotherapeutics, 16(4),
860-869.
